Roche Diagnostics Foresees Revenue Increase From DNA Microarray Area
This article was originally published in PharmAsia News
Executive Summary
At a briefing in Tokyo, Roche Diagnostics Japan President Wataru Ogawa said he foresees a revenue of ¥4.1 billion ($38.2 million), a 24 percent increase in its Applied Science business. He said ¥0.5 billion ($4.63 million) will come from new entrants such as DNA microarrays. Ogawa also anticipates a strong demand for point-of-care testing devices in time for a new health guidance that takes effect in April. Roche Diagnostics plans on launching 12 new products in 2008, including high sensitivity DNA microarrays and real-time cell analysis systems. (Click for more-Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.